The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironmentPan Zhang, Meirong Huo, Xuxin Chu et al.|Biomaterials|2022Cited by 68